There were 577 press releases posted in the last 24 hours and 394,484 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Dova Pharmaceuticals Provides Update on Development Strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT)

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image